Cargando…

Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic

Detalles Bibliográficos
Autores principales:	Díez, Javier, Bayes‐Genis, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721902/ https://www.ncbi.nlm.nih.gov/pubmed/29054841 http://dx.doi.org/10.1161/JAHA.117.007665

Ejemplares similares

In vivo experience with natural scaffolds for myocardial infarction: the times they are a-changin’
por: Perea-Gil, Isaac, et al.
Publicado: (2015)

Commentary: A Review of Prognosis Model Associated With Cardiogenic Shock After Acute Myocardial Infarction
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity‐2
por: Gerber, Yariv, et al.
Publicado: (2017)

Different Effects on Protein Expression of CDR132L, an Antisense Inhibitor of miR-132, and Standard Therapies for Myocardial Infarction
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis
por: Yang, Hyun Suk, et al.
Publicado: (2016)

Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
por: Arnaldos-Carrillo, María, et al.
Publicado: (2023)

Lack of prognostic significance for major adverse cardiac events of soluble suppression of tumorigenicity 2 levels in patients with ST-segment elevation myocardial infarction
por: Kim, Min, et al.
Publicado: (2021)

Microvascular Obstruction in ST-Segment Elevation Myocardial Infarction: Looking Back to Move Forward. Focus on CMR
por: Rios-Navarro, Cesar, et al.
Publicado: (2019)

Identification of Temporal and Region-Specific Myocardial Gene Expression Patterns in Response to Infarction in Swine
por: Prat-Vidal, Cristina, et al.
Publicado: (2013)

Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis
por: Aimo, Alberto, et al.
Publicado: (2022)

Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
por: Huang, Dong-Hui, et al.
Publicado: (2016)

Organisation: Voluntary, or Compelled?
Publicado: (1918)

Association of soluble suppression of tumorigenicity 2 protein with new-onset atrial fibrillation in patients with acute ST-segment elevation myocardial infarction undergoing primary PCI
por: Zhao, Ting-ting, et al.
Publicado: (2023)

Mesenchymal Stem Cells Induce Expression of CD73 in Human Monocytes In Vitro and in a Swine Model of Myocardial Infarction In Vivo
por: Monguió-Tortajada, Marta, et al.
Publicado: (2017)

The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Neoinnervation and neovascularization of acellular pericardial-derived scaffolds in myocardial infarcts
por: Gálvez-Montón, Carolina, et al.
Publicado: (2015)

Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure
por: Öncel, Can Ramazan
Publicado: (2018)

Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
por: Iannazzo, Francesco, et al.
Publicado: (2022)

Evidence for the routine collection and clinical utilisation of patient‐reported outcomes is compelling: It is time to jump on the bandwagon
por: Girgis, Afaf
Publicado: (2021)

Contributing Chemistry and Compelling Physics
Publicado: (2013)

Is the Act of Compelling Vaccination Unconstitutionial?
por: Wyatt, Thomas M.
Publicado: (1892)

A Cell-Enriched Engineered Myocardial Graft Limits Infarct Size and Improves Cardiac Function: Pre-Clinical Study in the Porcine Myocardial Infarction Model
por: Perea-Gil, Isaac, et al.
Publicado: (2016)

Heart Failure Treatment by Device
por: Bayés-Genis, Antoni
Publicado: (2020)

The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny
por: Bayes-Genis, Antoni
Publicado: (2022)

Impact of a ‘stent for life’ initiative on post‐ST elevation myocardial infarction heart failure: a 15 year heart failure clinic experience
por: Bayes‐Genis, Antoni, et al.
Publicado: (2017)

Circulating linoleic acid at the time of myocardial infarction and risk of primary ventricular fibrillation
por: Oliveras, Teresa, et al.
Publicado: (2022)

Relationship among LRP1 expression, Pyk2 phosphorylation and MMP‐9 activation in left ventricular remodelling after myocardial infarction
por: Revuelta‐López, Elena, et al.
Publicado: (2017)

Prognostic Value of New‐Generation Troponins in ST‐Segment–Elevation Myocardial Infarction in the Modern Era: The RUTI‐STEMI Study
por: Cediel, Germán, et al.
Publicado: (2017)

Electromechanical Conditioning of Adult Progenitor Cells Improves Recovery of Cardiac Function After Myocardial Infarction
por: Llucià‐Valldeperas, Aida, et al.
Publicado: (2016)

Livedoid vasculopathy: a compelling diagnosis
por: Freitas, Thiago Quadrante, et al.
Publicado: (2018)

Mitophagy and Neuroinflammation: A Compelling Interplay
por: Charmpilas, Nikolaos, et al.
Publicado: (2023)

Our Journey Through Advanced Therapies to Reduce Post-Infarct Scarring
por: Roura, Santiago, et al.
Publicado: (2021)

Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure
por: Gül, İbrahim, et al.
Publicado: (2017)

Comparison of two preclinical myocardial infarct models: coronary coil deployment versus surgical ligation
por: Gálvez-Montón, Carolina, et al.
Publicado: (2014)

Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction
por: Fernández-Bergés, Daniel, et al.
Publicado: (2020)

Deep Learning Analyses to Delineate the Molecular Remodeling Process after Myocardial Infarction
por: Iborra-Egea, Oriol, et al.
Publicado: (2021)

Circulating virome and inflammatory proteome in patients with ST-elevation myocardial infarction and primary ventricular fibrillation
por: Oliveras, Teresa, et al.
Publicado: (2022)

Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction
por: Cediel, Germán, et al.
Publicado: (2018)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Pascual-Figal, Domingo, et al.
Publicado: (2021)

Interviewing users: how to uncover compelling insights
por: Portigal, Steve
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_m9ii0pcognasijqds38hko7pej